Rationale and design of a randomized, double‐blind, event‐driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial

AIMS: Thrombin is a critical element of crosstalk between pathways contributing to worsening of established heart failure (HF). The aim of this study is to explore the efficacy and safety of rivaroxaban 2.5 mg bid compared with placebo (with standard care) after an exacerbation of HF in patients wit...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Heart Fail
Main Authors: Zannad, Faiez, Greenberg, Barry, Cleland, John G.F., Gheorghiade, Mihai, van Veldhuisen, Dirk J., Mehra, Mandeep R., Anker, Stefan D., Byra, William M., Fu, Min, Mills, Roger M.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Ltd 2015
Assuntos:
Study Design
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5029775/
https://ncbi.nlm.nih.gov/pubmed/25919061
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ejhf.266
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados